U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C17H26N4O4S
Molecular Weight 382.478
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALPIROPRIDE

SMILES

CNS(=O)(=O)C1=C(N)C=C(OC)C(=C1)C(=O)NCC2CCCN2CC=C

InChI

InChIKey=QRQMZZNDJGHPHZ-UHFFFAOYSA-N
InChI=1S/C17H26N4O4S/c1-4-7-21-8-5-6-12(21)11-20-17(22)13-9-16(26(23,24)19-2)14(18)10-15(13)25-3/h4,9-10,12,19H,1,5-8,11,18H2,2-3H3,(H,20,22)

HIDE SMILES / InChI

Molecular Formula C17H26N4O4S
Molecular Weight 382.478
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Alpiropride (RIV-2093) is a dopamine D2-receptor antagonist structurally similar to sulpiride. Alpiropride has been given orally for the treatment and prophylaxis of migraine.

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
LD50 in male mice (mg/kg): 44 i.v.; 184 i.p.; 204 s.c.; 3600 orally
Route of Administration: Other
Substance Class Chemical
Record UNII
1768UW0XS1
Record Status Validated (UNII)
Record Version